Dontsov D.V. 1
Ambalov Y.M. 1
Mamedova N.I. 1
1 Rostov State Medical University
Use in patients with chronic hepatitis C combination antiviral therapy with interferon and ribavirin achieves in most cases, sustained virologic response, which indicates a positive treatment outcome. However, at some patients during treatment can be development of various side effects. A special place among the adverse events of specific therapy for chronic hepatitis C take haematological disorders. The sharp decline in the number of peripheral blood erythrocytes, neutrophils and platelets often requires a dose reduction of antiviral drugs or complete cessation of the therapy. In this scientific research, we examined the nature of changes a number of indicators of immune status and cytokine profile at the patients with chronic hepatitis C who had development cytopenia during the receive combination antiviral therapy. Was found significantly associated with the identified patients immunological changes and the degree of their hematological complications pursued causal treatment of chronic hepatitis C. These results we plan to use at the future for creation of method forecasting of development hematological complications at patients with chronic hepatitis C, who receives combined anti-virus therapy.